NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase I/II Clinical Trial of NC-6004 in Combination With 5-FU and Cetuximab as First-line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Sponsor: NanoCarrier Co., Ltd.
This PHASE1/PHASE2 trial investigates Carcinoma, Squamous Cell of Head and Neck and is currently completed. NanoCarrier Co., Ltd. leads this study, which shows 10 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
May 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Jan 2019 — May 2019 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
May 2017 — Mar 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Mar 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NanoCarrier Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .